Filing Flows › Comparisons › KRYS vs TWST
Krystal Biotech vs Twist Bioscience: KRYS and TWST compared
Krystal Biotech is the larger company: $127M of revenue in its latest quarter (Q3 2026) against $118M for Twist Bioscience (Q3 FY26). Krystal Biotech is growing faster (+30% against +23% a year earlier). Krystal Biotech is more profitable, with an operating margin of 55.9% against -30.6%.
Where the money goes: KRYS and TWST
Krystal Biotech (KRYS) · Q3 2026
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Twist Bioscience (TWST) · Q3 FY26
Twist Bioscience, Q3 FY26: revenue $118M (+23% year over year), operating margin -30.6%, net loss $35.1M, operating cash flow $1.1M. The chart follows the revenue to costs, profit and cash.
| Krystal Biotech (KRYS) | Twist Bioscience (TWST) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 FY26 |
| Revenue | $127M | $118M |
| Revenue growth, Y/Y | +30% | +23% |
| Operating margin | 55.9% | -30.6% |
| Net earnings | $63.1M | −$35.1M |
| Net margin | 49.5% | -29.6% |
| Operating cash flow | $91.2M | $1.1M |
| Free cash flow | $90.3M | — |
| Market value | — | $10.0B |
| Analysts’ mean target | — | $168.25 |
Where the revenue comes from
Twist Bioscience
- NGS applications: $61.8M (52%)
- DNA synthesis and protein solutions: $56.6M (48%)
Questions
Which is bigger, Krystal Biotech or Twist Bioscience?
Krystal Biotech is the larger company: $127M of revenue in its latest quarter (Q3 2026) against $118M for Twist Bioscience (Q3 FY26).
Is Krystal Biotech or Twist Bioscience growing faster?
Krystal Biotech is growing faster (+30% against +23% a year earlier).
Which is more profitable, Krystal Biotech or Twist Bioscience?
Krystal Biotech is more profitable, with an operating margin of 55.9% against -30.6%.
More: Krystal Biotech earnings · how Krystal Biotech makes money · Twist Bioscience earnings · how Twist Bioscience makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Aug 3, 2026). Fiscal quarters can end on different dates. Not investment advice.